Macrolide resistance in pneumococci—is it relevant? by unknown
PneumoniaCheng and Jenney Pneumonia  (2016) 8:10 DOI 10.1186/s41479-016-0010-1COMMENTARY Open AccessMacrolide resistance in pneumococci—is it
relevant?
Allen C. Cheng1,3,4* and Adam W. J. Jenney2,4,5Abstract
Macrolide antibiotics are widely used for a range of indications, including pneumonia. Both high-level and low-level
resistance to macrolides is increasing in pneumococci globally. Macrolide resistance in pneumococci is of limited clinical
relevance where ß-lactams remain the mainstay of treatment, such as for moderate/severe pneumonia; however, data
suggest that macrolides may not be able to be relied on as monotherapy for serious pneumococcal infections.
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thromycin, remain an important class of antimicrobials
for pneumococcal diseases. In Australia, azithromycin is
recommended in combination with ceftriaxone as em-
piric therapy for severe pneumonia, and clarithromycin
is a second line therapy for mild/moderate community-
acquired pneumonia. United States (US) guidelines are
currently being revised, but current recommendations
list macrolides as monotherapy for outpatient pneumo-
nia, and macrolides in combination with ß-lactams for
more severe pneumonia [1]. Although antibiotics are not
routinely recommended for otitis media, there is an
exception for high-risk children with otitis media (with
or without perforation), in which case azithromycin is
listed as one of several therapeutic options [2]. However,
the main selection pressure for resistant pneumococci
may come from its use in other indications such as
for non-pneumococcal respiratory tract infection [3],
bronchiectasis and chronic obstructive pulmonary
disease (COPD) [4], sexually transmitted diseases and
trachoma [5] (in different settings).
The increasing prevalence of macrolide-resistant
pneumococci has raised concerns about its place in ther-
apy. There are two major mechanisms mediating resist-
ance to macrolides. The ermB gene encodes a
methyltransferase that causes ribosomal methylation,* Correspondence: Allen.Cheng@monash.edu
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(MLSB) phenotype that reduces susceptibility to macro-
lides, lincosamide, and streptogramin B. This may be
expressed in a constitutive or inducible fashion [6]. mefA
codes for an antibiotic efflux pump removing the drug
from the target site. ermB tends to confer high level resist-
ance to macrolides with MICs >64 mg/l, whereas the ef-
flux mechanism results in lower MICs for erythromycin
(typically in the 1–16 mg/l range), compared to the Euro-
pean Committee on Antimicrobial Susceptibility Testing
(EUCAST) breakpoint for erythromycin (and clarithromy-
cin and azithromycin) of 0.25 mg/l. Other resistance
mechanisms also exist, including the mefE variant efflux
pump carried on the macrolide efflux genetic assembly
(mega), mutations in 23S rRNA and also in the L4 and
L22 proteins, and the rare ermA methyltransferase [7].
There are significant global differences in susceptibility
and the mechanisms of resistance. The highest rates of
resistance have been reported in East Asia (particularly
China, Japan, and South Korea) [8–10] and rapid increases
in resistance are occurring in Malaysia [11]. Globally,
ermB methyltransferase is more common, but the propor-
tion of isolates carrying this gene was higher in several
European countries, and less common in North America
[12]. Co-existence of both ermB and mefA is relatively
common in some settings. It has been reported at 15 % in
South Africa [13], but as high as 38 % in Russia and nearly
50 % in Vietnam [9].
Because of the association between resistance and
pneumococcal serotypes, conjugate pneumococcal vac-
cination has impacted on the epidemiology of resistance.le is distributed under the terms of the Creative Commons Attribution 4.0
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cause a significant and lasting decline in macrolide resist-
ance through reduction in carriage and disease due to se-
rotypes 6B, 9 V, 19 F and 23 F that can carry the erm or
mef genes [14, 15]. While the concerns about replacement
with drug-resistant non-vaccine serotypes such as 19A
have mostly been addressed by the 13-valent vaccine, re-
placement with other non-vaccine serotypes and capsular
transformation remains a concern [16–19].
Newer macrolides are concentrated intracellularly, and
this is thought to result in increased drug delivery to the
site of infection, and exposure to high concentrations of
drug following phagocytosis, which may overcome low
level resistance [20]. However, it has been suggested that
high-level resistance may be clinically relevant [21].
A case control study found that 24 % of patients with
erythromycin-resistant pneumococcal bacteraemia were
taking a macrolide at the time of bacteraemia, compared
to none of 136 matched controls with erythromycin-
sensitive pneumococcal bacteraemia [22].
The concern about resistance is mitigated by the clin-
ical use of this antibiotic class. There are few indications
for macrolide monotherapy for pneumococcal disease.
Macrolide monotherapy still has a place in the treatment
of community-acquired pneumonia in patients who are
allergic to ß-lactams. A meta-analysis compared clinical
outcomes in trials involving macrolides, stratified by
resistance to azithromycin [23]. Curiously, only 5 of the
13 trials involved community-acquired pneumonia, and
the remainder arguably involved patients in whom anti-
biotics are not indicated, such as chronic bronchitis,
acute bacterial sinusitis, and acute otitis media. Al-
though, overall a difference in clinical cure was seen in
patients with azithromycin resistance (89.4 % vs. 78.6 %,
p = 0.003), no differences were evident in patients with
pneumonia (94.2 % vs. 92.6 %, p = 0.63). Additionally,
clinical failure rates across all trials were similar in pa-
tients with low-level resistance (77.5 %) compared to
high-level resistance (79.2 %).
Another specific indication for macrolides is otitis
media in high-risk groups, such as Australian Indigenous
children. A clinical trial performed in a setting where
resistance was relatively uncommon suggests that clinical
outcomes of single dose azithromycin are similar to a
7-day course of amoxicillin, as well as reducing nasal
pneumococcal carriage [24]. However, a higher propor-
tion of the children on azithromycin that did carry
pneumococci had resistance (10 % vs. 3 %, p = 0.001), sug-
gesting that resistance may attenuate this benefit over time.
There are also a number of reasons for the use of macro-
lides other than their effect on bacteria. There has long been
interest in the anti-inflammatory effects of macrolides, and a
major indication for its use is in bronchiectasis particularly
associated with cystic fibrosis [25, 26]. A 2004 observationalstudy found a large and significance difference in mortality
between patients treated with a macrolide-based com-
bination of antibiotics compared with those on mono-
therapy [27]. Studies have since found a difference in
mortality (to a smaller degree) in pneumococcal
pneumonia [28, 29]. This difference may possibly be
explained by a lower severity of infection associated with
macrolide-resistant pneumococci [30].
Clinical trials adding a macrolide to ß-lactams have
not definitively demonstrated clinical benefit, but have
tested adjunctive macrolides for community-acquired
pneumonia generally, rather than pneumococcal pneu-
monia specifically. One trial found a shorter time to
clinical stability in patients with severe pneumonia
although the difference in this small trial was not
statistically significant [31]. Additionally, there were no
differences in other groups or outcomes including
length of stay or mortality. A recent cluster randomised
trial did not find any differences in mortality or hospital
length of stay [32]. The place of adjunctive macrolide
therapy in pneumococcal pneumonia remains uncertain.
In summary, macrolide resistance in pneumococci is of
limited clinical relevance where ß-lactams remain the
mainstay of treatment. However, data suggest that macro-
lides may not be able to be relied on as monotherapy for
serious pneumococcal infections.
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